Download pdf
Cross-border M&A Motivations and Performance Evaluation in the Healthcare Industry under the RCEP Framework — A Case Study of China Resources Pharmaceutical
- 1 Business School, Zhejiang Wanli University, Ningbo, Zhejiang, China
* Author to whom correspondence should be addressed.
Abstract
The research utilizes case analysis techniques to examine the driving forces behind, and the effectiveness of, the international corporate mergers and acquisitions (M&A) in China Resources Pharmaceutical within the RCEP structure. Research indicates that international mergers and acquisitions markedly improved the firm’s expertise in market expansion, technology acquisition, resource integration, and synergy effects. Such initiatives have stimulated an increase in revenue and profits, streamlined the cost framework, and further enhanced the firm’s brand prominence, innovative prowess, and competitive edge in the market. Enacting RCEP presents not only prospects for China Resources Pharmaceutical but also introduces obstacles including adherence to policies, cultural assimilation, and the merging of operations. The research suggests related strategic approaches to tackle these issues and boost the firm’s global competitive edge and market impact.
Keywords
RCEP, Cross-border M&A, M&A Motivations, Performance Evaluation
[1]. Wu, Y., Gu, X., Xiong, J. Strategic Considerations of China Regarding RCEP [J]. International Economic Review, 2013(4): 34-39.
[2]. Petri, P. A., Plummer, M. G. RCEP: Economic Implications for the Asia-Pacific [J]. Economics of Contemporary Asia, 2020, 34(2): 45-58.
[3]. Sugema, I. The Impact of RCEP on Regional Value Chains [J]. Asia-Pacific Economic Cooperation Review, 2021, 12(1): 87-96.
[4]. Wu, Z., Chen, Y., Zhang, P. The Impact of RCEP on the Development of China’s Pharmaceutical Trade [J]. China Pharmaceutical Import and Export, 2021(3): 21-28.
[5]. Ye, S. Motivations and Performance of M&A in Pharmaceutical Listed Companies: A Case Study of China Resources Sanjiu [J]. China Collective Economy, 2015(18): 94-96.
[6]. Jian, L. Business Performance of Chinese Enterprises’ Overseas M&A [J]. International Trade Issues, 2019, 39(2): 142-155.
[7]. Zhou, L., Cheng, B., Yu, Z. Motivations and Performance Evaluation of Cross-border M&A in the Pharmaceutical Industry under the "Belt and Road" Initiative: A Case Study of Fosun Pharma [J]. Journal of Hefei Normal University, 2023, 41(6): 1-6.
[8]. Dunning, J. H. Toward an Eclectic Theory of International Production: Some Empirical Tests [J]. Journal of International Business Studies, 1980, 11(1): 9-31.
[9]. Zhang, P. The Impact and Countermeasures of RCEP on China’s Pharmaceutical Industry [J]. China Pharmaceutical Import and Export, 2021, 18(2): 9-12.
[10]. Li, J. Motivations and Performance of Cross-border M&A in the Pharmaceutical Industry [J]. China Market, 2022, 46(3): 47-56.
[11]. Ni, W. Case Studies on the Synergy Effect of M&A among Listed Companies in China [M]. Beijing: China Economic Publishing House, 2019.
[12]. Wang, J., Huang, J. Motivations, Absorptive Capacity, and Innovation Performance of Cross-border M&A [J]. Management Science, 2021, 34(2): 45-58.
Cite this article
Feng,Y. (2024).Cross-border M&A Motivations and Performance Evaluation in the Healthcare Industry under the RCEP Framework — A Case Study of China Resources Pharmaceutical.Advances in Economics, Management and Political Sciences,112,6-12.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content
About volume
Volume title: Proceedings of the 2nd International Conference on Management Research and Economic Development
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).